Search form
Search
contact us
Navigation
home
boards
job ratings
cp wire
medtech news
pharmagather
catering
advertise
Legal Help
login/register
You are here
Home
»
companies
» KPI-121
KPI-121
Go or no go? Abbvie, Roche and Kala await key decisions
Go or no go? Abbvie, Roche and Kala await key decisions
EP Vantage
FDA
AbbVie
upadacatinib
Roche
Ignyta
entrectinib
Kala Pharmaceuticals
KPI-121
dry eye disease
Flag link:
FDA sets summer PDUFA dates for Acer, Kala therapies
FDA sets summer PDUFA dates for Acer, Kala therapies
BioCentury
FDA
Acer Therapeutics
Kala Pharmaceuticals
Edsivo celiprolol
KPI-121
Flag link:
Kala seeks FDA nod for dry eye disease drug
Kala seeks FDA nod for dry eye disease drug
Drug Delivery Business News
Kala Pharmaceuticals
FDA
KPI-121
dry eye disease
Flag link:
Kala Pharma reveals mixed Ph3 data for dry eye disease drug
Kala Pharma reveals mixed Ph3 data for dry eye disease drug
Drug Delivery Business News
Kala Pharmaceuticals
dry eye disease
KPI-121
Flag link:
